Appaloosa Statement Regarding SES Announcement
Appaloosa LP (“Appaloosa”), which manages funds holding a more than 7% economic interest in SES S.A. (“SES” or the “Company”), today issued the following statement in response to the SES Board of Directors’ (the “Board”) March 14, 2025 announcement.
“The satellite industry is evolving rapidly and, as the SES Board’s announcement makes clear, even glacial change at SES requires strong shareholder advocacy. The initial steps the SES Board is taking to modernize its structure are long-overdue and only came following shareholder pressure. However, much more can, and must, be done -- with a greater sense of urgency than is evident from the Board’s incrementalism.
“Specifically, adding a director with capital markets experience should be a priority as we believe such an appointment could prompt SES to finally begin addressing its underperforming capital investment practices and return value to shareholders. Likewise, the remaining board, capital structure and governance measures outlined in our proposed Resolutions are no less urgent. Shareholders should be disappointed that the Board did not even allow a vote on our capital structure and governance proposals.
“Appaloosa urges shareholders to vote in favor of Resolution 21 (which returns excess cash flow to shareholders) and will continue to advocate on behalf of all shareholders so that SES can be positioned for long-term success in today’s competitive environment.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317069935/en/
Contacts
Media
Jonathan Gasthalter/Nathaniel Garnick/Sam Fisher
Gasthalter & Co.
+1 (212) 257-4170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Becomes Official Partner of the Premier League17.3.2025 13:42:00 EET | Press release
Global sports company PUMA has signed an official agreement with the Premier League, the most-watched football league globally, as part of the company’s strategy to elevate the brand and strengthen its sports performance credibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317329567/en/ Global sports company PUMA has signed an official agreement with the Premier League, the most-watched football league globally, as part of the company’s strategy to elevate the brand and strengthen its sports performance credibility. This landmark collaboration will see PUMA become the Official Ball Supplier of the Premier League, which includes the provision of match balls at all League matches from the start of the 2025/26 season. Through this partnership, PUMA will also support the Premier League across multiple initiatives, from community-based football programs that nurture grassroots talent to high-impact marketing campaigns a
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa17.3.2025 13:00:00 EET | Press release
Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count. The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was: STOP-HS1: 45 mg: 40.2% vs. 29.7% [P=0.024] 75 mg: 40.6% vs 29.7% [P=0.022] STOP-HS2: 45 mg: 42.3% vs. 28.6% [P=0.004] 75 mg: 42.3% vs. 28.6% [P=0.003] Within
Adara Ventures Announces First Close of €100M AV4 Fund, Targeting Cybersecurity, AI & Digital Infrastructure17.3.2025 12:03:00 EET | Press release
Adara Ventures, the European venture capital firm specialising in early-stage deep tech investments, today announced the first close of its fourth flagship fund, AV4, targeting €100 million in capital commitments. This new fund reinforces Adara’s commitment to delivering strong returns in strategic sectors, including cybersecurity, applied AI, digital infrastructure, hardware components, digital health, and space. “We are immensely proud to announce the successful first close of AV4,” said Nico Goulet, Founding Partner of Adara Ventures. “Over the past nine months, we have secured in excess of €140 million in commitments across our fourth-generation funds. Alongside AV4, this includes Adara Ventures Energy (AVE), our first Pan-European fund dedicated to energy transition technologies. In one of the most challenging fundraising environments of the past 20 years, our strong DPI record, disciplined investment strategy, and focused fund model make AV4 a compelling opportunity for our limit
Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity17.3.2025 11:22:00 EET | Press release
Neutrophil to Lymphocyte ratio (NLR) is a critical biomarker of health of astronauts during space mission, and that of aging related illnesses, inflammaging, longevity and cancer prognosis. Oral consumption of AFO-202 strain of Aureobasidium pullulans produced Nichi BRITE and N-163 strain produced Neu REFIX together in pre-clinical and clinical studies having safely and beneficially modified NLR, are considered holding potential to help maintain astronauts health during space flight and also to bridge the gap between health span and life span by ‘Me-Byo’ phenomenon as published in Frontiers in Immunology while Neu REFIX standalone yielding enhanced dystrophin, an additional benefit that might help prevent muscle loss during space missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316966059/en/ Astronauts during space missions, deep-sea researchers, high-altitude climbers, and workers exposed to radiation hazards, ar
Cineca to House Italy’s Most Powerful Quantum Computer IQM Radiance 5417.3.2025 11:04:00 EET | Press release
Italian supercomputing centre Cineca today announced an agreement with IQM Quantum Computers, a global leader in superconducting quantum computers, to deliver the most powerful quantum computer in Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317715500/en/ IQM Radiance 54-qubit superconducting quantum computer IQM Radiance quantum computer, powered by IQM’s 54-qubit quantum processing unit (QPU), will be installed in the fourth quarter of 2025. The quantum computer will be integrated into Leonardo, which is one of the world’s fastest supercomputers. This will mark a major technology and innovation milestone for Italy and the larger quantum ecosystem. The installation will also be the first on-premises quantum computer at Cineca, which further consolidates the institution’s position as a centre of excellence for scientific computing internationally and strengthens Italy’s position in quantum computing. IQM intends
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom